Pharma and BioTech Daily
Pharma & Biotech Daily is a short, AI-generated, human-supervised briefing on what’s important in pharma and biotech.
Each weekday we condense key news on pipelines, deals, regulation and strategy into a quick audio update for people who build, run and invest in life sciences.
Produced by OWITH.ai, a boutique AI & data studio.
Sponsor the show: https://sponsor.owith.ai
Pharma and BioTech Daily
Latest Episodes
Sanofi's $1B Deal with Regeneron: Immunology Breakthroughs | Pharma and Biotech Daily
Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape is constantly evolving, with innovative partnerships, groundbreaking clinical trial results, and reg...
Eli Lilly's Retatrutide: 25% Weight Loss in Phase 3 Trial! | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest breakthroughs and trends shaping the landscape of medicine and treatment. In the ...
AstraZeneca's $2B Oncology Investment | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative developments across the pharmaceutical and biotech sectors, highl...
AbbVie Juvmo FDA Approved: Parkinson's Breakthrough | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent updates in these sectors have highlighted significant scientific advancements, regulatory milestones, and p...
Merck's FDA Win: Welireg & Lenvima Breakthrough | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries is currently experiencing a wave of transformative changes, from strategic corpo...